Pier Giuseppe Pelicci
Molecular Biology · 2000–2017
A researcher in the Science corpus: 13 papers; trusts 10 researchers and is trusted by 4 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 140 citations into it; #8,857 of 17,773 by trust here, #1,476 by citations
- Oncology — 90 citations into it
- Aging — 17 citations into it
- Geriatrics and Gerontology — 13 citations into it
Whom Pier Giuseppe Pelicci trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Pier Giuseppe Pelicci overall
Papers from Pier Giuseppe Pelicci's perspective
Ordered by how strongly the researchers Pier Giuseppe Pelicci trusts endorse each paper. Same corpus, a different order for every researcher.
- The language of covalent histone modifications (Nature)
- Deacetylation of p53 modulates its effect on cell growth and apoptosis (Nature)
- The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. (Proceedings of the National Academy of Sciences of the United States of America)
- Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. (Cell)
- Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase (Nature)
- Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans (Nature)
- Histone deacetylases and cancer: causes and therapies (Nature Reviews. Cancer)
- Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. (Molecules and Cells)
- Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. (Proceedings of the National Academy of Sciences of the United States of America)
- hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. (Cell)
Their papers
- Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor (2002) — 829 citations
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer (2006) — 2,200 citations
- Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication (2006) — 1,888 citations
- Human SIR2 deacetylates p53 and antagonizes PML/p53‐induced cellular senescence (2002) — 916 citations
- The tripartite motif family identifies cell compartments (2001) — 1,412 citations
- Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. (2010) — 946 citations
- Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. (2005) — 1,163 citations
- PML regulates p53 acetylation and premature senescence induced by oncogenic Ras (2000) — 892 citations
- Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells (2001) — 1,898 citations
- Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. (2005) — 1,909 citations
- Interrogating open issues in cancer precision medicine with patient-derived xenografts (2017) — 601 citations
- The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. (2009) — 746 citations
- Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? (2007) — 1,438 citations